Skip to main content
Clinical Trials/NCT07281885
NCT07281885
Recruiting
Not Applicable

A Randomized Control Trial on the Efficacy of Aromatherapy in Reducing Postoperative Nausea and Vomiting in Total Joint Replacement Patients

Hong Kong Buddhist Hospital1 site in 1 country159 target enrollmentStarted: September 1, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Hong Kong Buddhist Hospital
Enrollment
159
Locations
1
Primary Endpoint
Postoperative Nausea and Vomiting

Overview

Brief Summary

This study investigates the effectiveness of aromatherapy in reducing postoperative nausea and vomiting (PONV) among patients undergoing total joint replacement surgery, as these complications can lead to patient discomfort and prolonged recovery. It is designed as a randomized controlled trial involving 159 participants, who will be divided into three groups: an intervention group receiving aromatherapy patches (lavender-sandalwood or orange-ginger) plus standard care, a placebo group with a placebo patch plus standard care, and a control group receiving standard care alone. PONV will be measured using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) at baseline, 30 minutes after the intervention, and every 12 hours post-surgery. Additionally, patient satisfaction will be assessed through a 5-point Likert scale survey. The primary outcome of the study is the evaluation of RINVR scores, while the secondary outcome focuses on patient satisfaction levels. Data will be statistically analyzed using two-way ANOVA for repeated measures, with a significance level defined as p < 0.05. The study aims to determine the viability of aromatherapy as a complementary treatment for PONV, potentially improving postoperative care, enhancing patient satisfaction, and offering a cost-effective alternative to conventional anti emetic treatments if proven effective.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

After completion of written informed consent, participants would be randomly assigned to one of three groups (Intervention, Placebo, Control) by a designated clerical staff according to a blocked randomization list. Outcome assessors were independent, not knowing information regarding condition or grouping of participants.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged 18 or above
  • Patients scheduled for total joint replacement surgery at the HKBH

Exclusion Criteria

  • Cognitive impairments
  • Allergy to lavender, orange, ginger, or sandalwood
  • Allergy to micro-pore tape
  • Allergy to opioid medication
  • Undergoing other therapeutic treatment for PONV control, except prescribed medications

Arms & Interventions

Aromatherapy patches

Experimental

Standard Care + Use of Aromatherapy Patches

Intervention: Aromatherapy patches (Other)

Placebo patches

Placebo Comparator

Standard Care + Use of Placebo Patches

Intervention: Placebo Patches (Other)

Prescribed antiemetic treatment

Active Comparator

As standard care alone

Intervention: Control (Standard treatment) (Drug)

Outcomes

Primary Outcomes

Postoperative Nausea and Vomiting

Time Frame: Through study completion, an average of 24 hours at 4 timepoints: T0 (baseline at PACU), T1 (up to 30 minutes from applying intervention to reassessment at PACU), T2 (up to 12-hour post-intervention in ward), T3 (up to 24-hour post-intervention in ward).

as measured by Rhodes Index of Nausea, Vomiting, and Retching, which consists of 8-item 4-point Likert-scales for nausea, vomiting, and retching symptoms with a total score ranging from 0 to 32 for each time point. The higher scores indicate the higher severity of nausea, vomiting, and retching experienced by the patient.

Secondary Outcomes

  • Patient Satisfaction(Through study completion, an average of 24 hours at 4 timepoints: T0 (baseline at PACU), T1 (up to 30 minutes from applying intervention to reassessment at PACU), T2 (up to 12-hour post-intervention in ward), T3 (up to 24-hour post-intervention in ward).)

Investigators

Sponsor
Hong Kong Buddhist Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Choi Wan Chan

Advanced Practice Nurse, Principal Investigator

Hong Kong Buddhist Hospital

Study Sites (1)

Loading locations...

Similar Trials